Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ

被引:57
作者
Collins, Laura C. [1 ,2 ]
Achacoso, Ninah [3 ]
Haque, Reina [4 ]
Nekhlyudov, Larissa [2 ,5 ,6 ]
Fletcher, Suzanne W. [2 ,5 ]
Quesenberry, Charles P., Jr. [3 ]
Schnitt, Stuart J. [1 ,2 ]
Habel, Laurel A. [3 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Kaiser Permanente So Calif, Div Res, Oakland, CA USA
[4] Kaiser Permanente So Calif, Res & Evaluat, Pasadena, CA 91101 USA
[5] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA
[6] Harvard Vanguard Med Associates, Dept Med, Boston, MA USA
关键词
Ductal carcinoma in situ; Local recurrence; Risk factors invasive recurrence; BREAST-CONSERVING SURGERY; SURGICAL ADJUVANT BREAST; PATHOLOGICAL FEATURES; EUROPEAN ORGANIZATION; YOUNG AGE; CANCER; WOMEN; RADIATION; EXCISION; OUTCOMES;
D O I
10.1007/s10549-013-2539-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We aimed to identify clinicopathologic factors associated with local recurrence (LR) in a large population of DCIS patients treated with breast-conserving therapy between 1990-2001 in three health plans. Regression methods were used to estimate relative risks (RR) of LR. Among 2,995 patients, 325 had a LR [10.9 %; median follow-up 4.8 years (range 0.5-15.7)]. After adjusting for health plan and treatment, risk of LR was increased among women <45 years (RR = 2.1, 95 % CI 1.5-2.8), African-Americans (RR = 1.6; 95 % CI 1.1-2.1) and those with DCIS detected because of signs/symptoms (RR = 1.6; 95 % CI 1.2-2.0). After also adjusting for age and diagnosis year, pathologic features associated with increased LR were larger lesion size (RR = 2.9 for >= 20 low power fields of DCIS; 95 % CI 1.6-5.6) and involved (RR = 2.9; 95 % CI 1.6-5.2), or close margins (RR = 2.4; 95 % CI 1.6-3.8). Presentation with symptoms/signs was associated with increased risk of invasive recurrence; while African-American race, larger tumor size, and involved/close tumor margins were more strongly associated with increased risk of DCIS recurrence. Our findings suggest some risk factors differ for non-invasive and invasive LRs and that most factors are only moderately associated with increased LR risk. Future research efforts should focus on non-clinicopathologic factors to identify more powerful risk factors for LR.
引用
收藏
页码:453 / 460
页数:8
相关论文
共 37 条
[1]  
Abe O., 2010, Journal of the National Cancer Institute Monographs, P162, DOI 10.1093/jncimonographs/lgq039
[2]   Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy [J].
Adepoju, LJ ;
Symmans, WF ;
Babiera, GV ;
Singletary, SE ;
Arun, B ;
Sneige, N ;
Pusztai, L ;
Buchholz, TA ;
Sahin, A ;
Hunt, KK ;
Meric-Bernstam, F ;
Ross, MI ;
Ames, FC ;
Kuerer, HM .
CANCER, 2006, 106 (01) :42-50
[3]   Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853 [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Julien, JP ;
Fentiman, IS ;
Duval, C ;
Di Palma, S ;
Simony-Lafontaine, J ;
de Mascarel, I ;
van de Vijver, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2263-2271
[4]   Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-Year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group [J].
Bijker, Nina ;
Meijnen, Philip ;
Peterse, Johannes L. ;
Bogaerts, Jan ;
Van Hoorebeeck, Irene ;
Julien, Jean-Pierre ;
Gennaro, Massimiliano ;
Rouanet, Philippe ;
Avril, Antoine ;
Fentiman, Ian S. ;
Bartelink, Harry ;
Rutgers, Emiel J. Th. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3381-3387
[5]   Relationship Between Clinical and Pathologic Features of Ductal Carcinoma In Situ and Patient Age An Analysis of 657 Patients [J].
Collins, Laura C. ;
Achacoso, Ninah ;
Nekhlyudov, Larissa ;
Fletcher, Suzanne W. ;
Haque, Reina ;
Quesenberry, Charles P., Jr. ;
Puligandla, Balaram ;
Alshak, Najeeb S. ;
Goldstein, Lynn C. ;
Gown, Allen M. ;
Schnitt, Stuart J. ;
Habel, Laurel A. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (12) :1802-1808
[6]  
Ernster VL, 2002, JNCI-J NATL CANCER I, V94, P1546
[7]   Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? [J].
Evans, AJ ;
Pinder, SE ;
Ellis, IO ;
Wilson, ARM .
JOURNAL OF MEDICAL SCREENING, 2001, 8 (03) :149-151
[8]   Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
Wickerham, DL ;
Fisher, ER ;
Mamounas, E ;
Smith, R ;
Begovic, M ;
Dimitrov, NV ;
Margolese, RG ;
Kardinal, CG ;
Kavanah, MT ;
Fehrenbacher, L ;
Oishi, RH .
LANCET, 1999, 353 (9169) :1993-2000
[9]   Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience [J].
Fisher, B ;
Land, S ;
Mamounas, E ;
Dignam, J ;
Fisher, ER ;
Wolmark, N .
SEMINARS IN ONCOLOGY, 2001, 28 (04) :400-418
[10]  
Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO